Tudorza Pressair, an inhaled medication used for the long-term treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), has been discontinued by its manufacturer, AstraZeneca [1].
Why was Tudorza Pressair discontinued?
AstraZeneca announced the discontinuation of Tudorza Pressair in the United States, with the product being removed from the market [1]. The company has not publicly detailed the specific reasons behind this decision.
What are the alternatives to Tudorza Pressair?
For patients who were using Tudorza Pressair, alternative COPD treatments are available. These include other inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs), as well as combination therapies [2]. It is important for patients to consult with their healthcare provider to discuss the most appropriate treatment plan based on their individual needs and medical history.
When did Tudorza Pressair become unavailable?
Following the manufacturer's decision, Tudorza Pressair is no longer available for prescription or purchase in the United States [1].
What other drugs does AstraZeneca make for COPD?
AstraZeneca offers other respiratory medications, including Symbicort (budesonide/formoterol fumarate dihydrate) and Daliresp (roflumilast), which are used to manage COPD [3][4].
Are there any patent issues with Tudorza Pressair?
Information regarding specific patent challenges or expirations for Tudorza Pressair is not readily available in the provided context. DrugPatentWatch.com may offer more detailed patent information on pharmaceutical products [5].